Stock listing

NASDAQ:TRXB TRex Bio, Inc. Stock

Home listing (NASDAQ) of TRex Bio, Inc.

Follow TRex Bio, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:TRXB

$10.32 USD +0.92 (+9.9%)

Close on Nov 20, 2026

Past month -26.3% · daily closes, Oct 8, 2026 – Nov 20, 2026, adjusted for splits
Day range
$9.55 – $10.97 USDNov 20, 2026
Volume
92,988 sharesNov 20, 2026
Market cap
$283.1M USDAt the close on Nov 20, 2026 · price × 27.45M shares outstanding
Traded on an average day
$2.00M USDMedian day 88,700 shares · 1 day with no trades · last 3 months, Oct 8, 2026 – Nov 20, 2026
TRex Bio, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:TRXB · Home$10.32 USD+0.925 (+9.9%)92,988$9.83$10.97$9.55$9.39Close on Nov 20, 2026

Daily closes

Last 3 months, Oct 8, 2026 – Nov 20, 2026 · NASDAQ:TRXB · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$10.32+0.925+9.9%$9.83$10.97$9.5592,988
$9.39-0.61-6.1%$10.01$11.24$9.06261,001
$10.00-0.77-7.1%$10.77$11.11$9.61270,818
$10.77-2.90-21.2%$13.94$13.94$10.76123,216
$13.67-0.43-3.0%$14.10$14.10$13.3262,677
$14.10-0.15-1.1%$14.01$14.20$13.4145,615
$14.25+1.12+8.5%$13.05$14.48$12.60107,900
$13.13-0.46-3.4%$13.37$14.00$12.8282,500
$13.59+0.33+2.5%$13.38$14.25$13.04177,600
$13.26+0.27+2.1%$13.21$14.20$12.51150,200
$12.99-0.56-4.1%$13.55$13.55$12.51170,200
$13.55-0.18-1.3%$13.88$14.09$12.50122,100
$13.73+0.09+0.7%$13.57$14.05$13.33146,200
$13.64-0.10-0.7%$13.61$13.92$13.1054,900
$13.74+0.22+1.6%$13.66$13.86$13.1039,200
$13.52-0.91-6.3%$14.15$14.31$13.4233,600
$14.43+0.64+4.6%$13.94$14.49$13.3679,600
$13.79-0.08-0.6%$14.00$14.14$13.6942,900
$13.87+0.06+0.4%$13.80$14.64$13.5655,000
$13.81-1.69-10.9%$15.39$15.50$13.5181,200
$15.50+0.26+1.7%$15.45$16.21$15.0067,500
$15.24+0.80+5.5%$14.59$16.56$14.1088,600
$14.44-0.36-2.4%$14.80$15.01$14.2264,200
$14.80+0.79+5.6%$14.28$15.40$13.94113,500
$14.01-0.15-1.1%$14.17$14.40$13.5581,900
$14.16+0.66+4.9%$13.50$14.35$13.5088,700
$13.50-0.10-0.7%$13.41$14.05$13.21398,800
$13.60-0.43-3.1%$13.95$14.08$13.47121,900
$14.03+0.03+0.2%$14.19$14.36$13.75189,000
$14.000.000.0%$13.50$15.50$13.501,257,000
$14.00——$14.00$14.00$14.000
Ticker
NASDAQ:TRXB
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All TRex Bio, Inc. news

TRex Bio, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
1 in the last 12 months · 1 in all · newest Nov 13, 2026 · oldest 2026

Where TRex Bio, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:TRXB · Home listing · This pageNASDAQUnited StatesUSD
BOATS:TRXBBOATSUnited StatesUSD

Valuation

Statements: Year to Dec 31, 2025 · balance Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$205.0M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
Negative equity
Beta vs S&P 500
Under 6 months of closes

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
TRex Bio, Inc. · NASDAQ:TRXBUS$283.1MUS$205.0Mn/an/an/an/an/an/an/a
Contineum Therapeutics, Inc. · NASDAQ:CTNMUS$286.1MUS$47.86Mn/an/an/a1.2×n/a0.0×1.53
Greenwich LifeSciences, Inc. · NASDAQ:GLSIUS$282.6MUS$276.7Mn/an/an/an/an/an/a2.80
Precision BioSciences, Inc. · NASDAQ:DTILUS$282.5MUS$228.3Mn/a5.1×n/a5.5×−85.6%0.5×0.30
AP Biosciences, Inc. · TPEX:6945US$282.3MUS$215.7Mn/an/an/a4.0×n/a0.0×n/a
Fulcrum Therapeutics, Inc. · NASDAQ:FULCUS$281.8M−US$17.87Mn/an/an/a0.9×n/a0.0×0.42
Circio Holding ASA · OSL:CRNAUS$281.1MUS$225.9Mn/an/an/a5.3×n/a0.0×n/a
Relmada Therapeutics, Inc. · NASDAQ:RLMDUS$279.5MUS$77.42Mn/an/an/a1.4×n/a0.0×1.57
Benitec Biopharma Inc. · NASDAQ:BNTCUS$276.1MUS$99.78Mn/an/an/a1.6×n/a0.0×1.46
Galectin Therapeutics Inc. · NASDAQ:GALTUS$271.4MUS$293.0Mn/an/an/an/an/an/a1.20
Vicore Pharma Holding AB · OMXSTO:VICOUS$271.1MUS$182.5Mn/a467×n/a3.3×n/a0.0×n/a
Median of the othersUS$281.5MUS$199.1M236×2.4×−85.6%0.0×1.46

Forecasts

4 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
29.25 USD · Analysts' mean
EPS, year to Dec 2026
-2.00 · 1 analyst

Team and board

Officers

OfficerRole
Brandon HantsChief Financial Officer
Laura BernerChief Operating Officer
Carolyn GabusVice President, Clinical Operations
Ali ZarrinChief Scientific Officer
Ariella KelmanChief Medical Officer
Matt ChryslerHead of Portfolio & Alliance Management
Michael TownsendHead of Translational Medicine

Board

DirectorRole
Johnston ErwinChairman of the Board
Carol G. GallagherLead Independent Director
Joel S. MarcusDirector
Julie GilmoreDirector
Mike RossDirector
Peter HirthDirector
Travis CoyDirector

Events

QuarterResultsShare move
Q3 2026Nov 13, 2026 · After close−21.2%

Open Events

IPO

Priced at US$14.00 a share on Oct 8, 2026.

Price
US$14.00 a share
Shares offered
8,333,334 shares of common stock
Offering size
US$116.7 million
Underwriters' option
Up to 1,250,000 more shares
Listing
TRXB on the Nasdaq Global Select Market
Underwriters
J.P. Morgan, Evercore ISI, Cantor, Stifel, Wedbush PacGrow · In the order on the cover
Shares delivered
On or about Oct 13, 2026

Steps

StepWhen
Draft sent to the SEC in confidenceJun 26, 2026
Filed publiclySep 18, 2026
Amended onceOct 5, 2026
Shares registered with an exchangeOct 6, 2026
Declared effective by the SECOct 8, 2026
Final prospectus, with the priceOct 9, 2026

Open IPO · From the cover of the final prospectus (424B4) filed Oct 9, 2026

Financials

Annual, in USD

Income statement

LineFY2025FY2024
Revenue039.1M
Research and development29.8M35.0M
Selling, general and administrative8.04M6.50M
Operating income-37.8M-2.38M
Depreciation and amortization218.0K1.26M
EBITDA-37.6M-1.12M
Income before tax-34.8M-444.0K
Net income-34.8M-3.14M

Balance sheet

LineFY2025FY2024
Cash and equivalents15.2M47.5M
Short-term investments52.5M17.8M
Current assets71.4M66.8M
Total assets73.1M68.1M
Accounts payable371.0K527.0K
Current liabilities4.99M7.54M
Total liabilities165.3M126.0M
Shareholders' equity-92.1M-58.0M

Cash flow

LineFY2025FY2024
Cash from operations-41.4M-25.6M
Capital spending-68.0K-68.0K
Free cash flow-41.4M-25.6M
Cash from financing42.1M41.9M
Change in cash-32.3M-1.03M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 13, 2026Quarterly reportSEC
8-K · Current reportNov 13, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeOct 16, 2026Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeOct 16, 2026Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeOct 16, 2026Big-stake noticeSEC
4 · Change in ownershipOct 15, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeOct 15, 2026Big-stake noticeSEC
4 · Change in ownershipOct 13, 2026Insider tradeSEC
8-K · Current reportOct 13, 2026Current reportSEC
4 · Change in ownershipOct 13, 2026Insider tradeSEC
All 40 filings
FilingDateTypeFiled with
S-8 · Registration statement for employee plansOct 9, 2026Offer documentSEC
424B4 · ProspectusOct 9, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveOct 9, 2026Other filingsSEC
3 · Initial statement of ownershipOct 8, 2026Insider tradeSEC
4 · Change in ownershipOct 8, 2026Insider tradeSEC
4 · Change in ownershipOct 8, 2026Insider tradeSEC
4 · Change in ownershipOct 8, 2026Insider tradeSEC
4 · Change in ownershipOct 8, 2026Insider tradeSEC
4 · Change in ownershipOct 8, 2026Insider tradeSEC
4 · Change in ownershipOct 8, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 8, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 8, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 8, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 8, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 8, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 8, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 8, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 8, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 8, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 8, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 8, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 8, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 8, 2026Insider tradeSEC
CERT · Exchange's certificate of listingOct 8, 2026Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeOct 6, 2026Other filingsSEC
S-1/A · Registration statement, amendedOct 5, 2026Offer documentSEC
S-1 · Registration statementSep 18, 2026Offer documentSEC
DRS/A · Draft registration statement, amendedAug 21, 2026Offer documentSEC
DRS/A · Draft registration statement, amendedJul 31, 2026Offer documentSEC
DRS · Draft registration statementJun 26, 2026Offer documentSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from TRex Bio, Inc.’s releases

Common shares
27,445,682
Fully diluted
27,445,682

Fully diluted

LineShares
Common shares27,445,682

Share count over time

CountShares
Nov 22, 202627,445,682

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Transce3nd, LLC100<0.01%US$1,524Sep 30, 2026

Insider trades

TradeTradeSharesPriceValueDate
Alexandria Venture Investments, LLC
10% owner
Buy178,571USD 14.00US$2.5MOct 13, 2026
Svlsf VI, LLC
10% owner
Buy89,783USD 14.00US$1.26MOct 8, 2026
Svlsf VI, LLC
10% owner
Buy3,074USD 14.00US$43,036Oct 8, 2026

Big stakes

StakeStakeSharesDateFiling
ELI LILLY & Co19.90%5.48MOct 13, 2026Schedule 13D
Pfizer Inc7.20%1.97MOct 8, 2026Schedule 13G
SV Biotech Crossover Opportunities Fund LP7.00%1.92MOct 8, 2026Schedule 13D
Johnson & Johnson Innovation - JJDC, Inc.5.30%1.48MOct 13, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Ali ZarrinChief Scientific Officer · Since at least Nov 5, 2026
Ariella KelmanChief Medical Officer · Since at least Nov 5, 2026
Brandon HantsChief Financial Officer · Since at least Nov 5, 2026
Carol G. GallagherLead Independent Director · Since at least Nov 5, 2026
Carolyn GabusVice President, Clinical Operations · Since at least Nov 4, 2026
Joel S. MarcusDirector · Since at least Oct 13, 2026
Johnston ErwinChairman of the Board · Since at least Nov 5, 2026
Julie GilmoreDirector · Since at least Nov 5, 2026
Laura BernerChief Operating Officer · Since at least Nov 5, 2026
Matt ChryslerHead of Portfolio & Alliance Management · Since at least Nov 4, 2026
All 14 people
PersonSeat
Michael TownsendHead of Translational Medicine · Since at least Nov 4, 2026
Mike RossDirector · Since at least Nov 4, 2026
Peter HirthDirector · Since at least Nov 5, 2026
Travis CoyDirector · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about TRex Bio, Inc.